GT 3: what is the risk for acquiring tolerance to solvaldi, if treatment fails?
peppercito said
Jan 23, 2015
I just needed someone to say it. I will try SOL/RBV for 24 weeks.
If nothing more, I would be trying, and maybe this feeling of doom will leave me.
I did more digging and found that Sovaldi binds with a key catalytic site on the endoplasmic reticulum (ER) replication complex (which is my body) thus preventing viral replication. This poses a high barrier for the virus to overcome, a "hard target" if you will for the NS5B viral protein.
I will keep the forum posted on results.
thanks
mallani said
Jan 23, 2015
Hi pepper,
You are fairly correct with your SVR odds. Whether to wait for GS-5816 is a good question, as the SVR rates are higher. The Sovaldi/GS-5816 pill is still in Phase 3 trials- it may be approved later in 2015.
We have discussed resistant variants to Sovaldi. They undoubtedly occur, but appear to be transient. Sovaldi may be re-used without any apparent problem.
Personally, I would go for 24 weeks of Sovaldi and Ribavirin. The SVR rates are pretty good and if you relapse, retreatment later will not be a problem. Cheers.
peppercito said
Jan 23, 2015
I have GT 3e. the stats on the current recommended treatment Solvaldi/ Ribavirin for 24 weeks has a sustained SVR from 61-87%, depending on level of cirrhosis. I am 12 years post transplant so fibrosis/cirrhosis is very likely as is fatty liver with this genotype. I cannot take any form of interferon because of the transplant. I am 62. There is little or no data on transplants and age related factors.
I have been waiting for a co-formulation from Gilead of Solvaldi + GS-5816 which has much better odds at only 12 weeks. But have been rejected from clinical trials thus far.
Since Solvaldi appears to be the main component in future treatments targeting GT 3, I am concerned about acquiring a tolerance if I go with the current treatment- because of the subtle mutations that naturally occur in the viral genome.
Would a mutation significant enough to inhibit Solvadi effectively destroy the viris's ability to reproduce?
Should I go with current treatment now or hope for FDA approval of SOL + GS5816 for 2015? ....I can't see beyond that.
There are no Hepatologists in the Rio Grande Valley (Texas) and the Gastro's are not keeping up. I need some advice.
I just needed someone to say it. I will try SOL/RBV for 24 weeks.
If nothing more, I would be trying, and maybe this feeling of doom will leave me.
I did more digging and found that Sovaldi binds with a key catalytic site on the endoplasmic reticulum (ER) replication complex (which is my body) thus preventing viral replication. This poses a high barrier for the virus to overcome, a "hard target" if you will for the NS5B viral protein.
I will keep the forum posted on results.
thanks
Hi pepper,
You are fairly correct with your SVR odds. Whether to wait for GS-5816 is a good question, as the SVR rates are higher. The Sovaldi/GS-5816 pill is still in Phase 3 trials- it may be approved later in 2015.
We have discussed resistant variants to Sovaldi. They undoubtedly occur, but appear to be transient. Sovaldi may be re-used without any apparent problem.
Personally, I would go for 24 weeks of Sovaldi and Ribavirin. The SVR rates are pretty good and if you relapse, retreatment later will not be a problem. Cheers.
I have GT 3e. the stats on the current recommended treatment Solvaldi/ Ribavirin for 24 weeks has a sustained SVR from 61-87%, depending on level of cirrhosis. I am 12 years post transplant so fibrosis/cirrhosis is very likely as is fatty liver with this genotype. I cannot take any form of interferon because of the transplant. I am 62. There is little or no data on transplants and age related factors.
I have been waiting for a co-formulation from Gilead of Solvaldi + GS-5816 which has much better odds at only 12 weeks. But have been rejected from clinical trials thus far.
Since Solvaldi appears to be the main component in future treatments targeting GT 3, I am concerned about acquiring a tolerance if I go with the current treatment- because of the subtle mutations that naturally occur in the viral genome.
Would a mutation significant enough to inhibit Solvadi effectively destroy the viris's ability to reproduce?
Should I go with current treatment now or hope for FDA approval of SOL + GS5816 for 2015? ....I can't see beyond that.
There are no Hepatologists in the Rio Grande Valley (Texas) and the Gastro's are not keeping up. I need some advice.